Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection

Marulli, Giuseppe; Verderi, Enrico; Zuin, Andrea; Schiavon, Marco; Battistella, Lucia; Perissinotto, Egle; Romanello, Paola; Favaretto, Adolfo; Pasello, Giulia; Rea, Federico

doi:10.1093/icvts/ivu141

Cited by 18 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the pathology-based TNM stage classification has been considered to provide imprecise information about the survival rates [ 27 ]. Since outcomes can be different even among patients with the same disease stage, numerous studies are currently focusing on the evaluation of other biological and molecular prognostic factors as a potential complement of TNM staging system [ 24 , 25 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences

Blanco

Domínguez

Morales

et al. 2015

Pathology Research International

View full text Add to dashboard Cite

The prognostic role of N-glycolyl GM3 ganglioside (NeuGcGM3) expression in non-small cell lung carcinoma (NSCLC) still remains controversial. In this study, the NeuGcGM3 expression was reevaluated using an increased number of NSCLC cases and the 14F7 Mab (a highly specific IgG1 raised against NeuGcGM3). An immunohistochemical score integrating the percentage of 14F7-positive cells and the intensity of reaction was applied to reassess the relationship between NeuGcGM3 expression, some clinicopathological features, and the overall survival (OS) of NSCLC patients. The double and the triple expression of NeuGcGM3 with the epidermal growth factor receptor (EGFR) and/or its ligand, the epidermal growth factor (EGF), were also evaluated. NeuGcGM3 expression correlates with both S-Phase fraction (p = 0.006) and proliferation index (p = 0.000). Additionally, NeuGcGM3 expression was associated with a poor OS of patients in both univariate (p = 0.020) and multivariate (p = 0.010) analysis. Moreover, the double and/or the triple positivity of tumors to NeuGcGM3, EGFR, and/or EGF permitted us to identify phenotypes of NSCLC with a more aggressive biological behavior. Our results are in agreement with the negative prognostic significance of NeuGcGM3 expression in NSCLC patients. However, standardization of techniques to determine the expression of NeuGcGM3 in NSCLC as well as the implementation of a universal scoring system is recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences

Blanco

Domínguez

Morales

et al. 2015

Pathology Research International

View full text Add to dashboard Cite

show abstract

“…It is estimated that in 2035, this number will reach 3 million (2.1 million men and 0.9 million women) (1). On setting a diagnosis, about 30% of patients have already demonstrated local progression of the disease and future treatment is determined by the type and number of lymph nodes involved by the tumour (2). Patients with III A stage make up a heterogeneous group.…”

Section: Introductionmentioning

confidence: 99%

Five-year survival analysis and prognostic factors in patients operated on for non-small cell lung cancer with N2 disease

Łochowski¹,

Łochowska²,

Rębowski³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…On the other hand, the prognostic role of radiological response to induction chemotherapy has also been observed in a previous analysis performed by our group in surgically treated patients. 22 The obtained outcome results are also correlated to the feasibility of surgery and the absence of detrimental effect for pneumonectomies when performed in high-volume thoracic surgery centers. 23 , 24 …”

Section: Discussionmentioning

confidence: 85%

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment

Bonanno

Zago

Marulli

et al. 2016

OTT

Self Cite

View full text Add to dashboard Cite

ObjectivesIf concurrent chemoradiotherapy cannot be performed, induction chemotherapy followed by radical-intent surgical treatment is an acceptable option for non primarily resectable non-small-cell lung cancers (NSCLCs). No markers are available to predict which patients may benefit from local treatment after induction. This exploratory study aims to assess the feasibility and the activity of multimodality treatment, including triple-agent chemotherapy followed by radical surgery and/or radiotherapy in locally advanced NSCLCs.MethodsWe retrospectively collected data from locally advanced NSCLCs treated with induction chemotherapy with carboplatin (area under the curve 6, d [day]1), paclitaxel (200 mg/m2, d1), and gemcitabine (1,000 mg/m2 d1, 8) for three to four courses, followed by radical surgery and/or radiotherapy. We analyzed radiological response and toxicity. Estimated progression-free survival (PFS) and overall survival (OS) were correlated to response, surgery, and clinical features.ResultsIn all, 58 NSCLCs were included in the study: 40 staged as IIIA, 18 as IIIB (according to TNM Classification of Malignant Tumors–7th edition staging system). A total of 36 (62%) patients achieved partial response (PR), and six (10%) progressions were recorded. Grade 3–4 hematological toxicity was observed in 36 (62%) cases. After chemotherapy, 37 (64%) patients underwent surgery followed by adjuvant radiotherapy, and two patients received radical-intent radiotherapy. The median PFS and OS were 11 months and 23 months, respectively. Both PFS and OS were significantly correlated to objective response (P<0.0001) and surgery (P<0.0001 and P=0.002). Patients obtaining PR and receiving local treatment achieved a median PFS and OS of 35 and 48 months, respectively. Median PFS and OS of patients not achieving PR or not receiving local treatment were 5–7 and 11–15 months, respectively. The extension of surgery did not affect the outcome.ConclusionThe multimodality treatment was feasible, and triple-agent induction was associated with a considerable rate of PR. Patients achieving PR and receiving radical surgery or radiotherapy (53%) achieved a median OS of 4 years.

show abstract

Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection

Abstract: The use of IT for lymph node-positive NSCLC seems justified by low morbidity and/or mortality and good survival rates. Patients with response to IT showed greater benefit in the long term.

Cited by 18 publications

References 21 publications

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences

Five-year survival analysis and prognostic factors in patients operated on for non-small cell lung cancer with N2 disease

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment

Contact Info

Product

Resources

About